Free Trial

Dianthus Therapeutics (DNTH) Institutional Ownership

Dianthus Therapeutics logo
$23.80 +0.76 (+3.30%)
(As of 12/20/2024 05:16 PM ET)

Institutional Ownership Changes (13F Filings) for Dianthus Therapeutics (NASDAQ:DNTH)

Current
Institutional Ownership
Percentage
47.53%
Number of
Institutional Buyers
(last 12 months)
32
Total
Institutional Inflows
(last 12 months)
$232.97M
Number of
Institutional Sellers
(last 12 months)
12
Total
Institutional Outflows
(last 12 months)
$29.43M
Get DNTH Insider Trade Alerts

Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

DNTH Institutional Buying and Selling by Quarter

Dianthus Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/19/2024 Barclays PLC41,684$1.14M0.0%+390.5%0.141%
11/16/2024 Geode Capital Management LLC485,121$13.29M0.0%-2.8%1.639%
11/15/2024 Barclays PLC41,684$1.14M0.0%+390.5%0.141%
11/15/2024 Jane Street Group LLC20,316$556K0.0%N/A0.069%
11/15/2024 Wellington Management Group LLP53,785$1.47M0.0%N/A0.182%
11/15/2024 State Street Corp821,131$22.48M0.0%+101.4%2.774%
11/15/2024 Point72 Asset Management L.P.437,700$11.98M0.0%+151.3%1.479%
11/15/2024 Janus Henderson Group PLC949,334$25.94M0.0%+40.5%3.207%
11/15/2024 HighVista Strategies LLC19,808$542K0.2%N/A0.067%
11/15/2024 Point72 Asia Singapore Pte. Ltd.8,568$235K0.0%-78.3%0.029%
11/14/2024 Fred Alger Management LLC9,633$264K0.0%+52.5%0.033%
11/14/2024 Braidwell LP493,687$13.52M0.4%+34.6%1.668%
11/14/2024 Vestal Point Capital LP395,000$10.82M0.8%-34.2%1.335%
11/14/2024 Walleye Capital LLC30,000$821K0.0%N/A0.101%
11/14/2024 MetLife Investment Management LLC13,939$382K0.0%+129.1%0.047%
11/13/2024 Great Point Partners LLC275,000$7.53M2.2%-63.7%0.929%
11/13/2024 FMR LLC4,403,148$120.56M0.0%+0.0%14.876%
11/12/2024 Charles Schwab Investment Management Inc.165,929$4.54M0.0%+142.0%0.565%
11/7/2024 Quest Partners LLC1,125$31K0.0%+112,400.0%0.004%
10/3/2024 SG Americas Securities LLC8,839$242K0.0%+104.0%0.030%
9/16/2024 Cubist Systematic Strategies LLC20,976$543K0.0%-13.1%0.071%
8/19/2024 Point72 Asset Management L.P.174,200$4.51M0.0%-50.5%0.594%
8/15/2024 The Manufacturers Life Insurance Company9,102$236K0.0%N/A0.031%
8/15/2024 Point72 Asia Singapore Pte. Ltd.39,504$1.02M0.2%+281.9%0.135%
8/14/2024 Fred Alger Management LLC6,317$163K0.0%-82.6%0.022%
8/14/2024 Cubist Systematic Strategies LLC20,976$543K0.0%-13.1%0.071%
8/14/2024 Point72 DIFC Ltd12,900$334K0.0%N/A0.044%
8/14/2024 Great Point Partners LLC757,929$19.62M3.8%+21.3%2.582%
8/14/2024 Marshall Wace LLP108,199$2.80M0.0%-4.2%0.369%
8/9/2024 Renaissance Technologies LLC88,604$2.29M0.0%-16.2%0.302%
8/9/2024 Dimensional Fund Advisors LP19,726$510K0.0%-9.2%0.067%
8/9/2024 Atlas Venture Life Science Advisors LLC136,979$3.55M0.4%-26.7%0.467%
8/9/2024 WINTON GROUP Ltd10,238$265K0.0%N/A0.035%
8/8/2024 American Century Companies Inc.30,432$788K0.0%+38.6%0.104%
8/1/2024 Rhumbline Advisers32,138$832K0.0%N/A0.109%
7/26/2024 Bank of New York Mellon Corp80,935$2.10M0.0%+860.5%0.276%
7/12/2024 SG Americas Securities LLC4,333$112K0.0%N/A0.015%
5/20/2024 Virtu Financial LLC12,995$390K0.0%N/A0.044%
5/17/2024 RA Capital Management L.P.2,333,000$69.99M0.9%N/A7.949%
5/16/2024 Janus Henderson Group PLC375,044$11.25M0.0%N/A1.278%
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

5/16/2024 Bain Capital Life Sciences Investors LLC2,992,028$89.76M7.2%N/A10.194%
5/14/2024 StemPoint Capital LP43,456$1.30M0.3%N/A0.148%
5/10/2024 Acadian Asset Management LLC4,012$120K0.0%-77.6%0.014%
5/10/2024 Vanguard Group Inc.537,828$16.14M0.0%+250.0%1.833%
5/6/2024 Atlas Venture Life Science Advisors LLC186,979$5.61M0.5%-21.1%0.637%
5/2/2024 Hussman Strategic Advisors Inc.21,000$630K0.1%N/A0.072%
2/15/2024 Octagon Capital Advisors LP554,000$5.76M0.9%+15.4%3.738%
2/14/2024 Vestal Point Capital LP135,000$1.40M0.1%N/A0.911%
2/13/2024 Tower Research Capital LLC TRC 2,430$25K0.0%N/A0.016%
12/6/2023 Citigroup Inc.3,868$53K0.0%N/A0.026%
11/15/2023 Laurion Capital Management LP36,393$497K0.0%N/A0.960%
11/14/2023 Avidity Partners Management LP1,217,554$16.64M0.7%N/A32.125%
11/13/2023 Atlas Venture Life Science Advisors LLC236,979$3.24M0.5%N/A6.249%
11/13/2023 Acadian Asset Management LLC22,299$303K0.0%N/A0.588%
11/13/2023 FMR LLC2,218,212$28.96M0.0%N/A58.497%
(Data available from 1/1/2016 forward)

DNTH Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of DNTH shares?

During the previous two years, 42 institutional investors and hedge funds held shares of Dianthus Therapeutics. The most heavily invested institutionals were FMR LLC ($120.56M), Bain Capital Life Sciences Investors LLC ($89.76M), RA Capital Management L.P. ($69.99M), Janus Henderson Group PLC ($25.94M), State Street Corp ($22.48M), Avidity Partners Management LP ($16.64M), and Vanguard Group Inc. ($16.14M).Learn more on DNTH's institutional investors.

What percentage of Dianthus Therapeutics stock is owned by institutional investors?

47.53% of Dianthus Therapeutics stock is owned by institutional investors. Learn more on DNTH's institutional investor holdings.

Which institutional investors have been buying Dianthus Therapeutics stock?

Of the 37 institutional investors that purchased Dianthus Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($2.99M), RA Capital Management L.P. ($2.33M), FMR LLC ($2.22M), Avidity Partners Management LP ($1.22M), Janus Henderson Group PLC ($648.71K), State Street Corp ($413.43K), and Vanguard Group Inc. ($384.18K).

How much institutional buying is happening at Dianthus Therapeutics?

Institutional investors have bought a total of 11,802,821 shares in the last 24 months. This purchase volume represents approximately $284.04M in transactions.

Which Dianthus Therapeutics major shareholders have been selling company stock?

Of the 12 institutional investors that sold Dianthus Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Great Point Partners LLC ($482.93K), Vestal Point Capital LP ($205K), Point72 Asset Management L.P. ($177.90K), Atlas Venture Life Science Advisors LLC ($100K), Point72 Asia Singapore Pte. Ltd. ($30.94K), Fred Alger Management LLC ($30.05K), and Renaissance Technologies LLC ($17.10K).

How much institutional selling is happening at Dianthus Therapeutics?

Institutional investors have sold a total of 1,084,621 shares in the last 24 months. This volume of shares sold represents approximately $29.43M in transactions.



This page (NASDAQ:DNTH) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners